Allergan scores year-end FDA nod for CGRP migraine med Ubrelvy, plans early 2020 launch

[cafead]

via Allergan’s Ubrelvy, formerly known as ubrogepant, passed FDA gatekeepers Monday, becoming the first oral CGRP drug for the acute treatment of migraines. The med is expected to face 2020 competition from Biohaven’s rimegepant. Allergan plans to launch in the first quarter next year.

article source

 

[Gerard Rotonda]

Allergan's has partnered with UpScript. UpScriptHealth is the only complete and fully integrated telehealth and pharmacy solution that powers direct-to-consumer pharmaceuticals. Peter Ax, CEO and Gerard Rotonda, Managing Director are the key contacts at UpScript. They set up a “Telehealth” button and provide a complete DTC solution on pharmaceutical company webpages for a customer to click “See a Doctor Now”.

UpScript has partnered with more than 20 major pharmaceutical companies that you know of. They are the future of Life Sciences and Direct-to-Consumer with telehealth. UpScript is the total evolution of what is happening in online healthcare

This is just one example of UpScript